Androgen-Deprivation Therapy Is More Than Palliation in Oligometastatic Prostate Cancer

PI3K and mTOR inhibitor, NVP-BEZ235, is more toxic than X-rays in prostate cancer cells

Background: Radiotherapy and adjuvant androgen deprivation therapy have historically been the first treatment choices for prostate cancer but treatment resistance often limits the capacity to effectively manage the disease. Therefore, alternative therapeutic approaches are needed. Here, the efficacies of radiotherapy and targeting the pro-survival cell signaling components epidermal growth fact...

Androgen Deprivation Therapy for Prostate Cancer

Androgen Deprivation Therapy for Prostate Cancer

AN D R O G E N D E P R I V A T I O N t h e r a p y ( A D T ; h e r e i n defined as medical or surgical castration) is the cornerstone treatment of advanced prostate cancer. In 1941, Huggins and Hodges first noted the beneficial effects of castration and injection of estrogens in patients with metastatic prostate cancer. The biological basis of the effect of ADT, the almost ubiquitous expressio...

Androgen deprivation therapy for prostate cancer.

CONTEXT Prostate cancer is the most common nonskin cancer and second most common cause of cancer mortality in US men. Androgen deprivation therapy (ADT), specifically surgical or medical castration, is the first line of treatment against advanced prostate cancer and is also used as an adjuvant to local treatment of high-risk disease. OBJECTIVE To review systematically the evidence on the risk...

p63 is more sensitive and specific than 34βE12 to differentiate adenocarcinoma of prostate from cancer mimickers

Objective(s): Prostate cancer is the world’s leading cause of cancer and the second cause of cancer-related death in men after lung cancer. Differentiation of prostate adenocarcinoma from benign prostate lesions and hyperplasia sometimes cannot be done on the basis of morphologic findings. Considering the fact that in the prostate adenocarcinoma there is no basal cell layer, basal cell markers ...